genomic differences between genders that may account for observed disparities between men and women with urothelial carcinoma (UC).
INTRODUCTION AND OBJECTIVES:
To develop a high accuracy non-invasive bladder cancer (BC) surveillance test focusing on the detection of non high-risk non-muscle invasive BC (NMIBC) tumours.
METHODS: A total of 597 urines from BC patients, controls and patients in follow up for BC (PFBC) were included. The study was divided into three phases. In the urinary biomarker discovery phase, 84 urines from BC and control patients were retrospectively included and analyzed by RNA sequencing. In the classifier development phase, a total of 132 selected genes from previous phase were evaluated by nCounterÒ in 214 prospectively collected urines from PFBC (98 with tumour). Then, a diagnostic classifier was generated by logistic regression. Finally, in the classifier validation phase, a multicentric and international cohort of 248 urine samples (134 BC and 114 nonrecurrent PFBC) was used to validate classifier performance.
RESULTS: A total of 521 genes were found differentially expressed between non high-risk NMIBC samples and all other groups (p<0.05). An 8-gene diagnostic classifier with an AUC of 0.893 was developed. Validation of the 8-gene classifier in an independent cohort of PFBC achieved an overall sensitivity (SN) and a negative predictive value (NPV) of 96% and 97%, respectively (AUC[0.823). Of note this accuracy was maintained in non high-risk NMIBC group (SN[94%; NPV[98%).
CONCLUSIONS: This 8-gene expression classifier has high SN and NPV in a real clinical scenario (PFBC). The use of this classifier can reduce the number of follow up cystoscopies in PFBC, although assessing its final place in clinical setting is necessary.
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MP63-15 COMPREHENSIVE MOLECULAR CLASSIFICATION OF BLADDER CANCER REVEALS DISTINCT PROGNOSTIC SUBGROUPS WITH DIFFERENT SENSITIVITIES TO IMMUNOTHERAPY
INTRODUCTION AND OBJECTIVES: Neoantigen-based immunotherapy is one of the hotspots in the field of immunotherapy against cancer. In this study, we intended to identify mutant peptides with neoantigen property in bladder cancer. Correlations between the immunoreactivity of candidate neoantigens and clinical manifestations were further analyzed.
METHODS: By using bioinformatics, HLA-A2(Human leukocyte antigen,HLA) restricted mutant (MT) peptides and wild type (WT) counterparts were selected based on whole exosome sequencing data of bladder cancer from the TCGA database. The binding affinity of predicted peptide pairs were determined by using T2 cell-based assay. Peptides with high affinity to HLA-A2 molecules were subjected to the determination of immunoreactivity in bladder cancer patients by using enzyme-linked immunospot (Elispot) assay upon in vitro stimulation. Clinical relevance to immune responses was analyzed.
